9 unknown, 1 completed, 1 not yet recruiting, 1 recruiting. 6 Phase 1, 5 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Unknown 4, Completed 1, Recruiting 1 |
| Phase 2 | 5 | Unknown 4, Recruiting 1 |
| Phase 4 | 1 | Unknown 1 |
Follow YY-20394: new trials by email Literature Review of YY-20394 trials Research Report on YY-20394
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A National Multicenter, Real-world Study of Linperlisib in the Treatment of Lymphoma Linperlisib - Indolent B-cell Lymphoma | Phase 4 | Unknown | Shanghai YingLi Pharmaceutical Co. Ltd. | 88 | 2024-04-30 | 2024-04-03 |
| Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma Linperlisib, Camrelizumab, Pegaspargase - Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma | Phase 1 / Phase 2 | Recruiting | Beijing Tongren Hospital | 43 | 2024-04-14 | 2024-04-19 |
| Real World Study of Linperlisib for Lymphoma Treatment Linperlisib - Focus on the Lymphoma Including B/T-cell Lymphoma | Not yet recruiting | Ruijin Hospital | 1000 | 2023-05-01 | 2023-05-18 | |
| A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma YY-20394 - Peripheral T/NK Cell Lymphoma (R/R PTCL) | Phase 2 | Unknown | Shanghai YingLi Pharmaceutical Co. Ltd. | 97 | 2022-05-01 | 2022-10-21 |
| A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer YY-20394 - Effectiveness，Safety，Thymic Cancer | Unknown | Shanghai YingLi Pharmaceutical Co. Ltd. | 58 | 2021-08-01 | 2021-07-23 | |
| A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma YY-20394 - Follicular Lymphoma | Phase 2 | Unknown | Shanghai YingLi Pharmaceutical Co. Ltd. | 140 | 2020-12-30 | 2020-05-07 |
| YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial YY-20394 - Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Unknown | Shanghai YingLi Pharmaceutical Co. Ltd. | 28 | 2020-08-20 | 2020-08-05 |
| A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies YY-20394 - Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma | Phase 1 | Completed | Shanghai YingLi Pharmaceutical Co. Ltd. | 43 | 2020-06-15 | 2024-06-13 |
| A Phase Ib Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma YY-20394 - Relapsed or Refractory Peripheral T-Cell Lymphoma | Phase 1 | Unknown | Shanghai YingLi Pharmaceutical Co. Ltd. | 58 | 2020-03-30 | 2021-01-28 |
| A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors YY-20394 - Advanced Solid Tumor | Phase 1 | Unknown | Shanghai YingLi Pharmaceutical Co. Ltd. | 50 | 2019-08-01 | 2019-08-08 |
| A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma YY-20394 - Lymphoma, Follicular | Phase 2 | Unknown | Shanghai YingLi Pharmaceutical Co. Ltd. | 123 | 2019-04-29 | 2020-05-11 |
| A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies YY-20394 - B-cell Lymphoma Recurrent, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Unknown | Shanghai YingLi Pharmaceutical Co. Ltd. | 42 | 2017-12-25 | 2018-12-10 |
Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell, Peripheral (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Shanghai YingLi Pharmaceutical Co. Ltd. (10) · Beijing Tongren Hospital (1) · Ruijin Hospital (1)
China (7) · United States (1)
Hanying Bao, PhD (2) · Jun Ma (1) · Liang Wang, M.D. (1) · Ranjit Nair, MD. (1) · Zhiming Li, PHD (1)
PMID 15016963, PMID 18616528, PMID 18794884, PMID 20626398, PMID 24450857, PMID 24450858, PMID 24615776, PMID 24615777, PMID 34425850, PMID 39923042